DIEXF Inhibitors
DIEXF inhibitors comprise a spectrum of chemical compounds that directly or indirectly suppress the functional activity of DIEXF by targeting various signaling pathways and biological processes. Rapamycin, by inhibiting the mTORC1 complex through its interaction with FKBP12, leads to the suppression of downstream cellular processes that DIEXF is involved in, thereby reducing DIEXF activity. Similarly, LY294002 and Wortmannin, both inhibitors of PI3K, impair the PI3K/AKT pathway, crucial for cell survival and growth, culminating in a decrease in DIEXF activity as this pathway is a key regulator of DIEXF function. The AKT inhibitor Triciribine further attenuates the PI3K/AKT/mTOR pathway, resulting in a dampened signaling cascade and subsequent diminishment of DIEXF function. In parallel, inhibitors of cell cycle regulators such as PD 0332991, which targets CDK4 and CDK6, and Kenpaullone, a GSK3 and CDK inhibitor, indirectly reduce DIEXF activity by influencing the cell cycle and Wnt signaling pathways, respectively, both of which are integral to the processes DIEXF regulates.
Additionally, PD 98059 and U0126, both MEK inhibitors, along with SP600125, a JNK inhibitor, and SB 203580, targeting p38 MAP kinase, modulate the MAPK pathway, which plays a significant role in cell growth and stress responses, where DIEXF's role is pertinent. The resultant decrease in MAPK/ERK signaling from these inhibitors ultimately leads to a reduction in DIEXF activity. Gö 6983's inhibition of PKC isoforms also contributes to the decrease in DIEXF activity by altering protein function regulation through phosphorylation, a process in which DIEXF is implicated. Collectively, these inhibitors work through distinct but interconnected pathways to effectively diminish the functional activity of DIEXF, highlighting the complex regulatory network that DIEXF is a part of and providing a comprehensive understanding of the mechanisms through which DIEXF activity can be inhibited.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin targets the mTOR pathway by binding to FKBP12 and forming a complex that inhibits the mTORC1 complex. DIEXF is involved in cellular processes that are downstream of mTOR signaling; rapamycin's action would, therefore, lead to diminished activity of DIEXF by suppressing the pathway it is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which blocks the PI3K/AKT pathway, a critical signal transduction system that promotes cell survival and growth. As PI3K influences pathways that DIEXF is involved in, inhibition by LY 294002 would lead to a decrease in DIEXF activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly binds to the p110 subunit of PI3K, thereby inhibiting its activity. The inhibition of PI3K/AKT pathway by wortmannin would result in reduced functional activity of DIEXF by impeding the pathway's signaling that DIEXF relies on. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the activation of AKT, which is part of the PI3K/AKT/mTOR pathway, a crucial cell signaling pathway. By inhibiting AKT, Triciribine would, therefore, lead to a reduction in DIEXF activity as it would diminish the signaling cascade required for DIEXF function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
PD 0332991 is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. CDKs are essential for the cell cycle progression. As DIEXF is associated with processes regulated by the cell cycle, the inhibition of CDKs would indirectly diminish the functional activity of DIEXF. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Kenpaullone is a potent inhibitor of CDKs as well as glycogen synthase kinase 3 (GSK3). By inhibiting GSK3, Kenpaullone can alter the Wnt signaling pathway, which in turn could decrease the activity of DIEXF through downstream effects on cellular processes that DIEXF is involved in. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is an inhibitor of mitogen-activated protein kinase kinase (MEK), which is a part of the MAPK/ERK pathway. By blocking MEK, PD 98059 can indirectly lead to a decrease in DIEXF activity by diminishing the pathway's signaling that DIEXF relies on for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which has a role in cell stress and inflammatory responses. Inhibiting JNK can alter the cell's response to stress and inflammation, indirectly diminishing DIEXF's activity through changes in cellular stress pathways with which DIEXF is associated. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is an inhibitor of p38 MAP kinase, which is involved in the response to stress stimuli and cytokines. By inhibiting p38, SB 203580 would lead to a reduction in DIEXF activity by decreasing the functional activity of pathways that DIEXF is involved in. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. MEK inhibitors can reduce the activity of the MAPK/ERK pathway, which is important for cell growth and differentiation. This would indirectly diminish DIEXF's functional activity through decreased MAPK/ERK signaling. | ||||||